TODOS MED LTD ORD - TOMDF STOCK NEWS

Todos Medical, Ltd. (OTCQB: TOMDF) announced its participation in the World Antiviral Congress 2022 from November 28 to December 1, 2022, at the Loews Coronado Bay Resort, San Diego. The congress will focus on advancements in antiviral research. Todos Medical specializes in developing diagnostics for early cancer detection and has acquired Provista Diagnostics to enhance its capabilities. The company also works on neurodegenerative disease diagnostics, including Alzheimer's. For more information, visit Todos Medical.

Todos Medical (OTCQB: TOMDF) has secured a 5-year exclusive agreement with Smart Automated Retail Network (SARN) to distribute immune support supplements, including its product Tollovid, across over 21,000 U.S. grocery stores and airport locations. This partnership capitalizes on the growing demand for unattended retail, especially for health products. SARN aims to convert 25% of store space for automated retail, addressing labor shortages in grocery outlets. The global market for immune health supplements is expected to reach $132 billion by 2028, indicating strong growth potential for Todos.

Todos Medical, Ltd. (OTCQB: TOMDF) reported a remarkable 89% increase in Q3 2022 revenues, reaching $1.914 million compared to $1.01 million in Q3 2021, driven by expanded PCR testing services. The company achieved key milestones, including the launch of non-COVID PCR tests and a Long COVID panel. Operating losses decreased to $(1.802 million) from $(2.497 million) in the previous year, while net loss improved to $(5.661 million). Todos aims for sustainable growth through its new subsidiary, Todos Botanicals, and plans for further product launches in 2023.

Todos Medical, Ltd. (OTCQB: TOMDF) announced the upcoming conference call for its Q3 2022 earnings and business update on November 15, 2022, at 8:30 AM ET. The call will provide insights into the company's financial performance, business developments, and future outlook.

Todos focuses on cancer diagnostics and recently acquired Provista Diagnostics to enhance its offerings. The company is also involved in developing tests for neurodegenerative disorders and has a joint venture for 3CL protease-based solutions. Investors will be keen on earnings and potential growth strategies discussed during the call.

Todos Medical, Ltd. (OTCQB: TOMDF) has announced the termination of its license and distribution agreement for Tollovid™ products with T-Cell Protect Hellas S.A. T-Cell Protect has confirmed this termination and will remove Todos Medical’s branding from its marketing materials. This decision highlights Todos Medical's strategic shift away from this partnership as it focuses on its proprietary diagnostic solutions aimed at early cancer detection and its other product developments in the healthcare sector.

Todos Medical, Ltd. (OTCQB: TOMDF), announced its President & CEO, Gerald Commissiong, will present a corporate update on November 8, 2022, at 3:30 PM during BioFuture™ NYC 2022. The company specializes in medical diagnostics and cancer detection solutions. Todos has developed proprietary technologies, including the Todos Biochemical Infrared Analyses for cancer screening. Recent acquisitions include Provista Diagnostics, enhancing its PCR COVID testing capabilities. Todos is also advancing blood tests for neurodegenerative disorders like Alzheimer’s and has formed a joint venture for 3CL protease diagnostics and therapeutics.

Todos Medical, Ltd. (OTCQB: TOMDF) has submitted an Emergency Use Authorization (EUA) application for its PCR MonkeyPox Test to the FDA. The test shows a sensitivity of 0.95 viral copies per reaction. CEO Gerald Commissiong emphasized the commitment to advanced PCR testing for emerging infectious diseases amid regulatory changes limiting testing methods. The company, also known for its cancer diagnostics, recently acquired Provista Diagnostics, enhancing its laboratory capabilities for COVID and MonkeyPox testing.

Todos Medical, Ltd. (OTCQB: TOMDF) is advancing its Long COVID initiatives, preparing to crowdfund for trials of its antiviral products, Tollovir™ and Tollovid™. The company will present at the Emerging Growth Conference on October 12, 2022. Provista Diagnostics has successfully launched PCR testing services in Florida, targeting various infections and planning an expansion. Todos is also developing the Videssa breast cancer blood test and a saliva-based MonkeyPox diagnostic. Additionally, a national stock exchange listing is underway, enhancing market presence.

Todos Medical, Ltd. (OTCQB: TOMDF) announced the successful pilot launch of its PCR testing services in Dunnellon, Florida, with a 24-hour turnaround for results. Services cover various infections, including COVID and MonkeyPox. The company onboarded over 10 physician practices and plans to expand to other underserved areas nationwide. CEO Gerald Commissiong emphasized a shift towards non-COVID testing, anticipating increased revenue from these services. The launch also includes a Long COVID panel aimed at improving patient monitoring, paired with future cancer diagnostic offerings.